Pseudomonas aeruginosa
Conditions
Sponsors
Shenzhen Third People's Hospital
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Patients with Multidrug-Resistant Bacterial Infections: These patients must have undergone drug susceptibility testing at our hospital or at other hospitals of grade 3 or above.The test results should be based on the available evidence; 2. Pathogenic Bacteria Infections: The bacteria causing the infection should meet one of the following conditions: Total Antibiotic Resistance: The pathogenic bacterial pair exhibits resistance to all antibiotics. Resistance to Key Antibiotics: The pathogenic bacteria are resistant to key antibiotics. In Vitro Sensitivity but In Vivo Resistance: The pathogenic bacteria are sensitive to key antibiotics in vitro but ineffective in vivo (defined as recurrent infection of the patient's target bacteria for two months or more with continuous, unclear treatment periods). Use of Sensitive Antibiotics: Pathogenic bacteria are subject to the use of antibiotics to which they are sensitive (e.g., in patients with organ toxicity or hypersensitivity to these antibiotics); 3. Phage Therapy:At least one lytic phage must be available for screening; 4.The phage therapy can be administered through various methods, including spraying, external application, atomized inhalation, perfusion, and topical administration via infection foci or catheters; 5. Informed Consent:Subjects and their families (or guardians) should fully read, understand, and sign the consent form.
Exclusion criteria
Exclusion criteria: 1. Bacterial Infections:Can be effectively managed with antibiotic therapy; 2. Phage Therapy:No suitable phage found to be effective against the infection; 3. Administration Routes for Bacteriophages:No viable administration routes available, or the potential routes (such as nebulized inhalation, catheterization, perfusion, or wet compresses) are contraindicated; 4. Patient Refusal:The patient declines to undergo bacteriophage therapy; 5. Study Eligibility:Patients deemed unsuitable for study participation by the investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Patient survival and safety; | — |
Secondary
| Measure | Time frame |
|---|---|
| Clinical symptoms improvement;Bacterial clearance or reduction; Temperature;Blood routine;C-reactive protein;Procalcitonin;Inflammatory cytokine spectrum;Clinical imaging indicators;The effective rate of phage treatment for 2 weeks is that the number of sputum (urine, drainage) smears and cultures of target bacteria and the negative conversion ratio are reported.; | — |
Countries
China
Contacts
Public ContactLu Hongzhou
The Third People's Hospital of Shenzhen
Outcome results
None listed